Adicet Bio Statistics
Total Valuation
Adicet Bio has a market cap or net worth of $92.20 million. The enterprise value is -$29.71 million.
Important Dates
The last earnings date was Wednesday, May 13, 2026, after market close.
| Earnings Date | May 13, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Adicet Bio has 10.50 million shares outstanding. The number of shares has increased by 43.59% in one year.
| Current Share Class | 9.35M |
| Shares Outstanding | 10.50M |
| Shares Change (YoY) | +43.59% |
| Shares Change (QoQ) | +3.64% |
| Owned by Insiders (%) | 0.80% |
| Owned by Institutions (%) | 37.50% |
| Float | 7.43M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 0.64 |
| P/TBV Ratio | 0.67 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 7.65, with a Debt / Equity ratio of 0.10.
| Current Ratio | 7.65 |
| Quick Ratio | 7.52 |
| Debt / Equity | 0.10 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -1,928.80 |
Financial Efficiency
Return on equity (ROE) is -72.19% and return on invested capital (ROIC) is -42.89%.
| Return on Equity (ROE) | -72.19% |
| Return on Assets (ROA) | -39.44% |
| Return on Invested Capital (ROIC) | -42.89% |
| Return on Capital Employed (ROCE) | -75.32% |
| Weighted Average Cost of Capital (WACC) | 10.96% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$1.07M |
| Employee Count | 102 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -23.61% in the last 52 weeks. The beta is 1.51, so Adicet Bio's price volatility has been higher than the market average.
| Beta (5Y) | 1.51 |
| 52-Week Price Change | -23.61% |
| 50-Day Moving Average | 7.66 |
| 200-Day Moving Average | 9.48 |
| Relative Strength Index (RSI) | 58.28 |
| Average Volume (20 Days) | 111,505 |
Short Selling Information
The latest short interest is 587,837, so 5.60% of the outstanding shares have been sold short.
| Short Interest | 587,837 |
| Short Previous Month | 553,507 |
| Short % of Shares Out | 5.60% |
| Short % of Float | 7.92% |
| Short Ratio (days to cover) | 5.23 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -113.80M |
| Pretax Income | -108.83M |
| Net Income | -108.83M |
| EBITDA | -107.76M |
| EBIT | -113.80M |
| Earnings Per Share (EPS) | -$13.35 |
Full Income StatementBalance Sheet
The company has $137.59 million in cash and $13.90 million in debt, with a net cash position of $123.69 million or $11.78 per share.
| Cash & Cash Equivalents | 137.59M |
| Total Debt | 13.90M |
| Net Cash | 123.69M |
| Net Cash Per Share | $11.78 |
| Equity (Book Value) | 140.07M |
| Book Value Per Share | 14.59 |
| Working Capital | 121.77M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$91.34 million and capital expenditures -$283,000, giving a free cash flow of -$91.62 million.
| Operating Cash Flow | -91.34M |
| Capital Expenditures | -283,000 |
| Depreciation & Amortization | 6.04M |
| Net Borrowing | -150,000 |
| Free Cash Flow | -91.62M |
| FCF Per Share | -$8.73 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Adicet Bio does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -43.59% |
| Shareholder Yield | -43.59% |
| Earnings Yield | -115.80% |
| FCF Yield | -97.49% |
Analyst Forecast
The average price target for Adicet Bio is $34.83, which is 296.70% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $34.83 |
| Price Target Difference | 296.70% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 6 |
| Revenue Growth Forecast (3Y) | n/a |
| EPS Growth Forecast (3Y) | n/a |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on December 30, 2025. It was a reverse split with a ratio of 1:16.
| Last Split Date | Dec 30, 2025 |
| Split Type | Reverse |
| Split Ratio | 1:16 |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 1 |
